Monopar Historical Income Statement
| MNPR Stock | USD 20.10 0.39 1.98% |
Historical analysis of Monopar Therapeutics income statement accounts such as Total Operating Expenses of 7.5 M can show how well Monopar Therapeutics performed in making a profits. Evaluating Monopar Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Monopar Therapeutics's future profits or losses.
Monopar |
About Monopar Income Statement Analysis
Monopar Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Monopar Therapeutics shareholders. The income statement also shows Monopar investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Monopar Therapeutics Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Total Revenue
Total revenue comprises all receipts Monopar Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Monopar Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' Selling General Administrative is relatively stable compared to the past year. As of 11/25/2024, Total Other Income Expense Net is likely to grow to about 450.5 K, while Operating Income is likely to drop (9.3 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 9.1M | 10.5M | 8.8M | 7.5M | Research Development | 6.5M | 7.6M | 5.6M | 5.3M |
Monopar Therapeutics income statement Correlations
Click cells to compare fundamentals
Monopar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Monopar Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 98.9K | 81.9K | 24.0K | 21.2K | 24.4K | 23.2K | |
| Selling General Administrative | 2.4M | 2.4M | 2.6M | 2.9M | 3.2B | 3.4B | |
| Operating Income | (4.3M) | (6.5M) | (9.1M) | (10.5M) | (8.8M) | (9.3M) | |
| Net Income From Continuing Ops | (4.2M) | (6.3M) | (9.1M) | (10.5M) | (9.5M) | (10.0M) | |
| Ebit | (4.3M) | (13.1M) | (9.1M) | (10.5M) | (8.4M) | (8.8M) | |
| Research Development | 2.0M | 4.1M | 6.5M | 7.6M | 5.6M | 5.3M | |
| Total Operating Expenses | 4.3M | 6.5M | 9.1M | 10.5M | 8.8M | 7.5M | |
| Income Before Tax | (4.2M) | (6.3M) | (9.1M) | (10.5M) | (8.4M) | (8.8M) | |
| Total Other Income Expense Net | 98.9K | 204.3K | 24.0K | 21.2K | 429.0K | 450.5K | |
| Net Income Applicable To Common Shares | (3.2M) | (4.2M) | (6.3M) | (9.1M) | (8.2M) | (8.6M) | |
| Net Income | (4.1M) | (6.2M) | (9.1M) | (10.5M) | (8.4M) | (8.8M) | |
| Net Interest Income | 98.9K | 81.9K | 24.0K | 21.2K | 343.6K | 360.8K | |
| Interest Income | 98.9K | 81.9K | 24.0K | 21.2K | 343.6K | 360.8K | |
| Other Operating Expenses | 4.3M | 6.5M | 9.1M | 10.5M | 8.8M | 8.3M | |
| Ebitda | (4.3M) | (6.6M) | (9.1M) | (10.5M) | 429.0K | 450.5K | |
| Depreciation And Amortization | 4.3K | 6.5M | 48.0K | 21.2K | 8.8M | 9.3M | |
| Income Tax Expense | (98.9K) | (81.9K) | (24.0K) | (21.2K) | (8.8K) | (9.3K) |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Monopar Stock
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | AGL | agilon health | PairCorr |
| 0.81 | NKTX | Nkarta Inc | PairCorr |
| 0.79 | MTEM | Molecular Templates | PairCorr |
| 0.78 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.